Geneva Capital Management LLC Sells 12,263 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geneva Capital Management LLC lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 865,582 shares of the medical instruments supplier’s stock after selling 12,263 shares during the quarter. LeMaitre Vascular makes up approximately 1.4% of Geneva Capital Management LLC’s portfolio, making the stock its 24th biggest holding. Geneva Capital Management LLC’s holdings in LeMaitre Vascular were worth $79,755,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in shares of LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after purchasing an additional 4,330 shares during the period. Townsquare Capital LLC raised its holdings in LeMaitre Vascular by 38.0% during the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after acquiring an additional 13,210 shares during the period. Barclays PLC raised its holdings in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after acquiring an additional 29,180 shares during the period. Compass Planning Associates Inc bought a new stake in LeMaitre Vascular during the 4th quarter valued at $567,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after acquiring an additional 11,395 shares during the period. Institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $87.00 on Thursday. The stock has a market cap of $1.96 billion, a P/E ratio of 47.54, a PEG ratio of 2.22 and a beta of 0.96. LeMaitre Vascular, Inc. has a fifty-two week low of $62.39 and a fifty-two week high of $109.58. The firm’s fifty day moving average price is $96.75 and its 200-day moving average price is $94.94.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. The ex-dividend date is Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.92%. LeMaitre Vascular’s payout ratio is 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.